Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKTURNA vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Hypertension (to lower blood pressure, alone or in combination with other antihypertensives)
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life is approximately 24 hours (range 20–40 hours), supporting once-daily dosing.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Primarily hepatic via CYP3A4; minor metabolism via other pathways. Excreted in feces (78%) and urine (22%).
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Primarily renal (88% as unchanged drug and metabolites, 33% as unchanged aliskiren); biliary/fecal elimination accounts for approximately 12%.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
Approximately 50% bound to plasma proteins (primarily albumin).
~10-20% bound to plasma proteins (primarily albumin).
Volume of distribution is approximately 1.7 L/kg, indicating extensive distribution into tissues.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral bioavailability is approximately 2.5% (low due to limited absorption and high first-pass metabolism); absorption is reduced by high-fat meal (by up to 50%).
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
Contraindicated in GFR <30 m L/min/1.73 m². For GFR ≥30 m L/min/1.73 m², no dose adjustment required.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not studied in severe hepatic impairment (Child-Pugh Class C).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Not approved for use in pediatric patients under 18 years of age due to lack of safety and efficacy data.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
No dose adjustment required in elderly patients; initiate therapy at 150 mg once daily and monitor renal function and blood pressure closely due to increased risk of hypotension and renal impairment.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
None
None
Fetal toxicity (avoid in pregnant women; discontinue if pregnancy detected),Hypotension in volume-depleted patients,Renal impairment (monitor renal function; risk of acute renal failure in patients with bilateral renal artery stenosis),Hyperkalemia (especially in patients with renal impairment, diabetes, or on potassium-sparing diuretics),Angioedema (discontinue immediately and manage appropriately)
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Pregnancy,History of angioedema with previous renin-angiotensin system inhibitors,Concomitant use with aliskiren in patients with diabetes (age- and renal-specific restrictions)
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
High-fat meals reduce aliskiren absorption; avoid consistent consumption with high-fat foods. Grapefruit juice may decrease aliskiren levels; avoid concurrent intake. No other significant food interactions.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal injury and death when used during the second and third trimesters. Risks include oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. First trimester exposure may also carry increased risk but is less well-defined.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
No data on presence in human milk; manufacturer advises against breastfeeding due to potential adverse effects in nursing infants, including hypotension and renal impairment.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No specific dose adjustments recommended; avoid use in pregnancy, especially during second and third trimesters, due to risk of fetal harm. If pregnancy occurs, discontinue promptly.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
TEKTURNA (aliskiren) is a direct renin inhibitor used for hypertension. Monitor renal function and potassium levels due to risk of hyperkalemia and renal impairment, especially in patients with diabetes, renal artery stenosis, or concomitant ACE/ARB use. Avoid use during pregnancy (category D). Contraindicated with cyclosporine and itraconazole due to increased aliskiren exposure.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take TEKTURNA once daily with or without food, but consistently either with a meal or without.,Avoid high-fat meals as they can reduce absorption.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not use salt substitutes containing potassium without consulting your doctor.,Report symptoms like muscle cramps, irregular heartbeat, or weakness (signs of hyperkalemia).,Stay hydrated and avoid dehydration (vomiting, diarrhea, excessive sweating) as it may increase side effects.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKTURNA vs ALDOMET, answered by our medical review team.
TEKTURNA is a Antihypertensive that works by Direct renin inhibitor that binds to renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and decreasing vasoconstriction and aldosterone secretion.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKTURNA and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKTURNA is: 150 mg orally once daily, starting dose; may increase to 300 mg once daily after 2-4 weeks if blood pressure not controlled, with or without food.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKTURNA and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKTURNA is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal injury and death when used during the second and third trimesters. Risks include oligohydramnios, fetal . ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.